Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $731,967 | $644,395 | $498,987 | $437,768 |
| % Growth | 13.6% | 29.1% | 14% | – |
| Cost of Goods Sold | $358,112 | $293,274 | $250,127 | $238,029 |
| Gross Profit | $373,855 | $351,121 | $248,860 | $199,739 |
| % Margin | 51.1% | 54.5% | 49.9% | 45.6% |
| R&D Expenses | $73,914 | $73,741 | $74,771 | $60,932 |
| G&A Expenses | $56,720 | $51,540 | $45,061 | $51,434 |
| SG&A Expenses | $94,522 | $80,393 | $66,592 | $68,920 |
| Sales & Mktg Exp. | $37,802 | $28,853 | $21,531 | $17,486 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $168,436 | $154,134 | $141,363 | $129,852 |
| Operating Income | $205,419 | $196,987 | $107,497 | $69,887 |
| % Margin | 28.1% | 30.6% | 21.5% | 16% |
| Other Income/Exp. Net | -$16,228 | -$27,609 | $7,366 | $14,044 |
| Pre-Tax Income | $189,191 | $169,378 | $114,863 | $83,931 |
| Tax Expense | $29,672 | $31,833 | $23,477 | $20,630 |
| Net Income | $159,519 | $137,545 | $91,386 | $62,116 |
| % Margin | 21.8% | 21.3% | 18.3% | 14.2% |
| EPS | 3.29 | 2.85 | 1.88 | 1.3 |
| % Growth | 15.4% | 51.6% | 44.6% | – |
| EPS Diluted | 3.06 | 2.6 | 1.74 | 1.25 |
| Weighted Avg Shares Out | 48,429 | 48,265 | 48,551 | 47,777 |
| Weighted Avg Shares Out Dil | 52,058 | 53,001 | 52,427 | 49,784 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,612 | $5,459 | $1,321 | $601 |
| Interest Expense | $30,343 | $27,158 | $1,846 | $885 |
| Depreciation & Amortization | $57,205 | $41,777 | $28,275 | $26,533 |
| EBITDA | $277,312 | $240,294 | $146,161 | $111,557 |
| % Margin | 37.9% | 37.3% | 29.3% | 25.5% |